Nilotinib hydrochloride monohydrate (BioDeep_00000760370)
代谢物信息卡片
Nilotinib monohydrochloride monohydrate
化学式: C28H25ClF3N7O2 (583.1710256)
中文名称: 尼罗替尼单盐酸盐单水合物
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.O.Cl
InChI: 1H
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Fatemeh Aghai-Trommeschlaeger, Sebastian Zimmermann, Anja Gesierich, Charis Kalogirou, Maria-Elisabeth Goebeler, Pius Jung, Theo Pelzer, Max Kurlbaum, Hartwig Klinker, Nora Isberner, Oliver Scherf-Clavel. Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Clinical biochemistry.
2022 Jul; 105-106(?):35-43. doi:
10.1016/j.clinbiochem.2022.04.011. [PMID: 35483452] - Natsuki Fukuda, Yumiko Akamine, Maiko Abumiya, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura. Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
Cancer chemotherapy and pharmacology.
2022 05; 89(5):609-616. doi:
10.1007/s00280-022-04419-1. [PMID: 35316401] - Souvik Banerjee, Shalini Yadav, Sourav Banerjee, Sayo O Fakayode, Jyothi Parvathareddy, Walter Reichard, Surekha Surendranathan, Foyez Mahmud, Ryan Whatcott, Joshua Thammathong, Bernd Meibohm, Duane D Miller, Colleen B Jonsson, Kshatresh Dutta Dubey. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study.
Journal of chemical information and modeling.
2021 11; 61(11):5469-5483. doi:
10.1021/acs.jcim.1c00524. [PMID: 34666487] - Ji-Hea Kim, Seung-Jin Lee, Ka-Won Kang, Byung-Hyun Lee, Yong Park, Byung-Soo Kim. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
Biochemical pharmacology.
2021 08; 190(?):114658. doi:
10.1016/j.bcp.2021.114658. [PMID: 34146540] - Tensei Hirasawa, Masafumi Kikuchi, Kensuke Shigeta, Shinya Takasaki, Yu Sato, Toshihiro Sato, Jiro Ogura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Masamitsu Maekawa, Nariyasu Mano. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Biomedical chromatography : BMC.
2021 Aug; 35(8):e5124. doi:
10.1002/bmc.5124. [PMID: 33772839] - Giovanni Caocci, Olga Mulas, Isabella Capodanno, Massimiliano Bonifacio, Mario Annunziata, Sara Galimberti, Luigiana Luciano, Mario Tiribelli, Bruno Martino, Fausto Castagnetti, Gianni Binotto, Patrizia Pregno, Fabio Stagno, Elisabetta Abruzzese, Monica Bocchia, Antonella Gozzini, Francesco Albano, Claudio Fozza, Debora Luzi, Fabio Efficace, Maria Pina Simula, Luigi Scaffidi, Claudia Baratè, Fiorenza De Gregorio, Rossella Stella, Gabriele Gugliotta, Francesca Pirillo, Malgorzata Monika Trawinska, Anna Sicuranza, Daniele Cattaneo, Immacolata Attolico, Emilia Scalzulli, Alessandra Iurlo, Robin Foà, Massimo Breccia, Giorgio La Nasa. Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Annals of hematology.
2021 Aug; 100(8):2005-2014. doi:
10.1007/s00277-020-04392-w. [PMID: 33388860] - Yung-Chih Kuo, He-Cheng Tsai, Rajendiran Rajesh. Glutathione Liposomes Carrying Ceftriaxone, FK506, and Nilotinib to Control Overexpressed Dopamine Markers and Apoptotic Factors in Neurons.
ACS biomaterials science & engineering.
2021 07; 7(7):3242-3255. doi:
10.1021/acsbiomaterials.1c00555. [PMID: 34189904] - Marwa S Serrya, Manar A Nader, Marwa E Abdelmageed. Hepatoprotective effect of the tyrosine kinase inhibitor nilotinib against cyclosporine-A induced liver injury in rats through blocking the Bax/Cytochrome C/caspase-3 apoptotic signaling pathway.
Journal of biochemical and molecular toxicology.
2021 Jun; 35(6):1-13. doi:
10.1002/jbt.22764. [PMID: 33710703] - Yuji Mukai, Yuka Yoshida, Tatsunari Yoshida, Takeshi Kondo, Nobuo Inotsume, Takaki Toda. Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis.
Therapeutic drug monitoring.
2021 06; 43(3):386-393. doi:
10.1097/ftd.0000000000000825. [PMID: 33065614] - Hesham Salem, Fatma A Abo Elsoud, Dina Heshmat, Ahmed Magdy. Resonance Rayleigh scattering technique-using erythrosine B, as novel spectrofluorimetric method for determination of anticancer agent nilotinib: Application for capsules and human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Apr; 251(?):119428. doi:
10.1016/j.saa.2021.119428. [PMID: 33485244] - Maiko Abumiya, Yumiko Akamine, Shiori Sato, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura. Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia.
Journal of clinical pharmacy and therapeutics.
2021 Apr; 46(2):382-387. doi:
10.1111/jcpt.13294. [PMID: 33108009] - Illias Tazi. [Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Bulletin du cancer.
2021 Apr; 108(4):435-437. doi:
10.1016/j.bulcan.2020.12.009. [PMID: 33663776] - Valeria Cagno, Gaelle Magliocco, Caroline Tapparel, Youssef Daali. The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro.
Basic & clinical pharmacology & toxicology.
2021 Apr; 128(4):621-624. doi:
10.1111/bcpt.13537. [PMID: 33232578] - G Sarlon-Bartoli, Q Michel, E Sarlon, M Carcopino-Tusoli, P Suchon, R Soler, M A Bartoli, D Brunet, P Morange, A Charbonnier. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
Journal de medecine vasculaire.
2021 Apr; 46(2):66-71. doi:
10.1016/j.jdmv.2021.02.002. [PMID: 33752848] - Sajjad Ahmad, Yasir Waheed, Saba Ismail, Saadia Bhatti, Sumra Wajid Abbasi, Khalid Muhammad. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
Molecules (Basel, Switzerland).
2021 Mar; 26(5):. doi:
10.3390/molecules26051446. [PMID: 33800013] - Tanya Simuni, Brian Fiske, Kalpana Merchant, Christopher S Coffey, Elizabeth Klingner, Chelsea Caspell-Garcia, David-Erick Lafontant, Helen Matthews, Richard K Wyse, Patrik Brundin, David K Simon, Michael Schwarzschild, David Weiner, Jamie Adams, Charles Venuto, Ted M Dawson, Liana Baker, Melissa Kostrzebski, Tina Ward, Gary Rafaloff. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
JAMA neurology.
2021 03; 78(3):312-320. doi:
10.1001/jamaneurol.2020.4725. [PMID: 33315105] - Umut Yılmaz, Aslıhan Pekmezci, Yalçın Gül, Ahmet Emre Eşkazan. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey.
Turkish journal of haematology : official journal of Turkish Society of Haematology.
2021 02; 38(1):79-81. doi:
10.4274/tjh.galenos.2020.2020.0472. [PMID: 32964857] - Kevin M Huang, Megan Zavorka Thomas, Tarek Magdy, Eric D Eisenmann, Muhammad Erfan Uddin, Duncan F DiGiacomo, Alexander Pan, Markus Keiser, Marcus Otter, Sherry H Xia, Yang Li, Yan Jin, Qiang Fu, Alice A Gibson, Ingrid M Bonilla, Cynthia A Carnes, Kara N Corps, Vincenzo Coppola, Sakima A Smith, Daniel Addison, Anne T Nies, Ralf Bundschuh, Taosheng Chen, Maryam B Lustberg, Joanne Wang, Stefan Oswald, Moray J Campbell, Pearlly S Yan, Sharyn D Baker, Shuiying Hu, Paul W Burridge, Alex Sparreboom. Targeting OCT3 attenuates doxorubicin-induced cardiac injury.
Proceedings of the National Academy of Sciences of the United States of America.
2021 02; 118(5):. doi:
10.1073/pnas.2020168118. [PMID: 33495337] - L Petrikova, K Slezakova, Z Sninska, L Harvanova, M Martisova, A Hatalova, M Mistrik, A Batorova, B Mladosievicova. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Bratislavske lekarske listy.
2021; 122(8):531-537. doi:
10.4149/bll_2021_085. [PMID: 34282617] - A Olivieri, G Mancini, J Olivieri, E Marinelli Busilacchi, M Cimminiello, S P Pascale, R Nuccorini, F Patriarca, P Corradini, A Bacigalupo, S Angelini, A Poloni, G Grillo, F Onida, M Martino, N Di Renzo, A Nagler, N Mordini, B Bruno, F Ciceri, F Bonifazi. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria).
Bone marrow transplantation.
2020 11; 55(11):2077-2086. doi:
10.1038/s41409-020-0902-9. [PMID: 32332918] - Ceren Elif Sener, Burcu Dogan Topal, Sibel A Ozkan. Effect of monomer structure of anionic surfactant on voltammetric signals of an anticancer drug: rapid, simple, and sensitive electroanalysis of nilotinib in biological samples.
Analytical and bioanalytical chemistry.
2020 Nov; 412(29):8073-8081. doi:
10.1007/s00216-020-02934-9. [PMID: 32978655] - Yoshinobu Seki, Ouki Nagano, Ryo Koda, Shinichi Morita, Go Hasegawa. Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
International journal of hematology.
2020 Oct; 112(4):584-591. doi:
10.1007/s12185-020-02913-x. [PMID: 32557125] - Youwen Tan, Yun Ye, Xingbei Zhou. Nilotinib-induced liver injury: A case report.
Medicine.
2020 Sep; 99(36):e22061. doi:
10.1097/md.0000000000022061. [PMID: 32899072] - Niklas J Koehl, René Holm, Martin Kuentz, Brendan T Griffin. Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats.
Pharmaceutical research.
2020 Jun; 37(7):124. doi:
10.1007/s11095-020-02841-9. [PMID: 32524365] - Elena Marinelli Busilacchi, Andrea Costantini, Giorgia Mancini, Giovanni Tossetta, Jacopo Olivieri, Antonella Poloni, Nadia Viola, Luca Butini, Anna Campanati, Gaia Goteri, Daniela Marzioni, Attilio Olivieri. Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2020 05; 26(5):823-834. doi:
10.1016/j.bbmt.2020.01.014. [PMID: 32006713] - Kareem M Saad, Rehab S Abdelrahman, Eman Said. Mechanistic perspective of protective effects of nilotinib against cisplatin-induced testicular injury in rats: Role of JNK/caspase-3 signaling inhibition.
Environmental toxicology and pharmacology.
2020 May; 76(?):103334. doi:
10.1016/j.etap.2020.103334. [PMID: 32059174] - Ashok Zakkula, Bhavesh Babulal Gabani, Ravi Kumar Jairam, Vinay Kiran, Umesh Todmal, Ramesh Mullangi. Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability.
Drug development and industrial pharmacy.
2020 Mar; 46(3):498-504. doi:
10.1080/03639045.2020.1730398. [PMID: 32067499] - Masoumeh Pirdadeh-Beiranvand, Abbas Afkhami, Tayyebeh Madrakian. Magnetic molecularly imprinted electrospun nanofibers for selective extraction of nilotinib from human serum.
Analytical and bioanalytical chemistry.
2020 Mar; 412(7):1629-1637. doi:
10.1007/s00216-020-02393-2. [PMID: 31965245] - Nourah Z Alzoman, Hadir M Maher, Shereen M Shehata, Norah O Abanmy. UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions.
Biomedical chromatography : BMC.
2019 Dec; 33(12):e4674. doi:
10.1002/bmc.4674. [PMID: 31376170] - Manuel García-Ferrer, Aneta Wojnicz, Gina Mejía, Dora Koller, Pablo Zubiaur, Francisco Abad-Santos. Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Clinical therapeutics.
2019 12; 41(12):2558-2570.e7. doi:
10.1016/j.clinthera.2019.10.009. [PMID: 31812340] - Lu Yu, Jing Liu, Xiaojun Huang, Qian Jiang. Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase.
Scientific reports.
2019 11; 9(1):17601. doi:
10.1038/s41598-019-54033-0. [PMID: 31772301] - Marwa S Zaghloul, Rehab S Abdelrahman. Nilotinib ameliorates folic acid-induced acute kidney injury through modulation of TWEAK and HSP-70 pathways.
Toxicology.
2019 11; 427(?):152303. doi:
10.1016/j.tox.2019.152303. [PMID: 31593741] - Tsuyoshi Aoyama, Yoshihiko Shibayama, Tatsuhiko Furukawa, Mitsuru Sugawara, Yoh Takekuma. Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells.
Biological & pharmaceutical bulletin.
2019 Nov; 42(11):1805-1813. doi:
10.1248/bpb.b19-00185. [PMID: 31434819] - Mahmoud M Samaha, Eman Said, Hatem A Salem. Nilotinib enhances β-islets integrity and secretory functions in a rat model of STZ-induced diabetes mellitus.
European journal of pharmacology.
2019 Oct; 860(?):172569. doi:
10.1016/j.ejphar.2019.172569. [PMID: 31351037] - Ronilda R D'Cunha, Daryl J Murry, Guohua An. Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.
Journal of pharmaceutical sciences.
2019 10; 108(10):3434-3442. doi:
10.1016/j.xphs.2019.05.028. [PMID: 31163185] - Ragesh R Nair, Richa Chauhan, Shivangi Harankhedkar, Manoranjan Mahapatra, Renu Saxena. Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
2019 Jul; 30(5):246-248. doi:
10.1097/mbc.0000000000000817. [PMID: 31310595] - Inga Mandac Rogulj, Vid Matišić, Borna Arsov, Luka Boban, Alen Juginović, Vilim Molnar, Dragan Primorac. Dasatinib-induced nephrotic syndrome: a case of phenoconversion.
Croatian medical journal.
2019 Jun; 60(3):250-254. doi:
10.3325/cmj.2019.60.250. [PMID: 31187953] - Fernando L Pagan, Michaeline L Hebron, Barbara Wilmarth, Yasar Torres-Yaghi, Abigail Lawler, Elizabeth E Mundel, Nadia Yusuf, Nathan J Starr, Joy Arellano, Helen H Howard, Margo Peyton, Sara Matar, Xiaoguang Liu, Alan J Fowler, Sorell L Schwartz, Jaeil Ahn, Charbel Moussa. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Pharmacology research & perspectives.
2019 04; 7(2):e00470. doi:
10.1002/prp2.470. [PMID: 30906562] - Rong Sun, Min-Yue Bao, Xin Long, Yuan Yuan, Miao-Miao Wu, Xin Li, Jin-Ku Bao. Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients.
Thoracic cancer.
2019 04; 10(4):715-727. doi:
10.1111/1759-7714.12989. [PMID: 30806032] - Bingcheng Liu, Ying Wang, Chunlin Zhou, Hui Wei, Dong Lin, Wei Li, Kaiqi Liu, Guangji Zhang, Shuning Wei, Yan Li, Benfa Gong, Yuntao Liu, Xiaoyuan Gong, Yingchang Mi, Jianxiang Wang. Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.
Annals of hematology.
2019 Mar; 98(3):633-645. doi:
10.1007/s00277-019-03594-1. [PMID: 30635765] - Niklas J Koehl, René Holm, Martin Kuentz, Brendan T Griffin. New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.
Pharmaceutical research.
2019 Feb; 36(4):56. doi:
10.1007/s11095-019-2590-y. [PMID: 30796596] - Takeshi Sasaki, Omar E Franco, Kohshi Ohishi, Yana Filipovich, Kenichiro Ishii, Susan E Crawford, Naoto Takahashi, Naoyuki Katayama, Yoshiki Sugimura, Simon W Hayward. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
The Prostate.
2019 02; 79(3):259-264. doi:
10.1002/pros.23730. [PMID: 30370673] - Masatomo Miura, Naoto Takahashi. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2019; 60(9):1140-1147. doi:
10.11406/rinketsu.60.1140. [PMID: 31597837] - Hari Krishna Ananthula, Scott Parker, Erin Touchette, R Mark Buller, Gopi Patel, Daniel Kalman, Johanna S Salzer, Nadia Gallardo-Romero, Victoria Olson, Inger K Damon, Tessa Moir-Savitz, Larry Sallans, Milton H Werner, Catherine M Sherwin, Pankaj B Desai. Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents.
BMC pharmacology & toxicology.
2018 Dec; 19(1):80. doi:
10.1186/s40360-018-0270-x. [PMID: 30514402] - Xianbin Tian, Hefei Zhang, Tycho Heimbach, Handan He, Aby Buchbinder, Mary Aghoghovbia, Florence Hourcade-Potelleret. Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor.
Journal of clinical pharmacology.
2018 12; 58(12):1533-1540. doi:
10.1002/jcph.1312. [PMID: 30179260] - Jing Yang, Beibei Zhang, Zifei Qin, Shishi Li, Jinjin Xu, Zhihong Yao, Xiaojian Zhang, Frank J Gonzalez, Xinsheng Yao. Efflux excretion of bisdemethoxycurcumin-O-glucuronide in UGT1A1-overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 (MRP1) as the glucuronide transporters.
BioFactors (Oxford, England).
2018 Nov; 44(6):558-569. doi:
10.1002/biof.1452. [PMID: 30334318] - Chien-Ting Lin, Po-Ren Hsueh, Shang-Ju Wu, Ming Yao, Bor-Sheng Ko, Chi-Cheng Li, Cheng-An Hsu, Jih-Luh Tang, Hwei-Fang Tien. Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2018 11; 24(11):2310-2315. doi:
10.1016/j.bbmt.2018.07.013. [PMID: 30026110] - Jyun-Pei Jhou, I-Shing Yu, Haw Hwai, Chih-Shan Chen, Pei-Lung Chen, Shiang-Jong Tzeng. The Lupus-Associated Fcγ Receptor IIb-I232T Polymorphism Results in Impairment in the Negative Selection of Low-Affinity Germinal Center B Cells Via c-Abl in Mice.
Arthritis & rheumatology (Hoboken, N.J.).
2018 11; 70(11):1866-1878. doi:
10.1002/art.40555. [PMID: 29774664] - Kendra Sweet, Lori Hazlehurst, Eva Sahakian, John Powers, Lisa Nodzon, Fadi Kayali, Kelly Hyland, Ashley Nelson, Javier Pinilla-Ibarz. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
Leukemia research.
2018 11; 74(?):89-96. doi:
10.1016/j.leukres.2018.10.002. [PMID: 30340199] - Matteo Molica, Emilia Scalzulli, Gioia Colafigli, Danilo Alunni Fegatelli, Fulvio Massaro, Roberto Latagliata, Robin Foà, Massimo Breccia. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
Annals of hematology.
2018 Oct; 97(10):1803-1808. doi:
10.1007/s00277-018-3375-9. [PMID: 29806063] - Maurizio Balestrino, Enrico Adriano. Statin-induced myopathy prevented by creatine administration.
BMJ case reports.
2018 Aug; 2018(?):. doi:
10.1136/bcr-2018-225395. [PMID: 30150340] - Noriyoshi Iriyama, Hiromichi Takahashi, Katsuhiro Miura, Yoshihito Uchino, Masaru Nakagawa, Yoshihiro Hatta, Masami Takei. Enhanced perforin expression associated with dasatinib therapy in natural killer cells.
Leukemia research.
2018 05; 68(?):1-8. doi:
10.1016/j.leukres.2018.02.014. [PMID: 29494851] - Junghoon Shin, Youngil Koh, Seo Hyun Yoon, Joo-Youn Cho, Dae-Young Kim, Kyoo-Hyung Lee, Hyeong-Joon Kim, Jae-Sook Ahn, Yeo-Kyeoung Kim, Jinny Park, Sang-Kyun Sohn, Joon Ho Moon, Yoo Jin Lee, Seonghae Yoon, Jeong-Ok Lee, June-Won Cheong, Kyoung Ha Kim, Sung-Hyun Kim, Hoon-Gu Kim, Hawk Kim, Seung-Hyun Nam, Young Rok Do, Sang-Gon Park, Seong Kyu Park, Sung Hwa Bae, Hun Ho Song, Dong-Yeop Shin, Doyeun Oh, Min Kyoung Kim, Chul Won Jung, Seonyang Park, Inho Kim. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
Cancer medicine.
2018 05; 7(5):1814-1823. doi:
10.1002/cam4.1450. [PMID: 29577674] - Deborah E Joekel, Britta Lundström-Stadelmann, Beat Müllhaupt, Andrew Hemphill, Peter Deplazes. Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis in vitro and in a mouse model.
Experimental parasitology.
2018 May; 188(?):65-72. doi:
10.1016/j.exppara.2018.04.002. [PMID: 29625098] - Elena Marinelli Busilacchi, Andrea Costantini, Nadia Viola, Benedetta Costantini, Jacopo Olivieri, Luca Butini, Giorgia Mancini, Ilaria Scortechini, Martina Chiarucci, Monica Poiani, Antonella Poloni, Pietro Leoni, Attilio Olivieri. Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
2018 02; 24(2):267-275. doi:
10.1016/j.bbmt.2017.10.039. [PMID: 29128554] - Tong Wang, Cai-Xia Li, Xiao-Chen Chen, Cai-Hong Gu, Dan Yang, Pu Wang, Qiu Zou, De-Pei Wu. [Correlation of Serum Concentration of Nilotinib with Clinical Efficacy in Patients with Chronic Myeloid Leukemia].
Zhongguo shi yan xue ye xue za zhi.
2018 Feb; 26(1):116-120. doi:
10.7534/j.issn.1009-2137.2018.01.019. [PMID: 29397828] - D S El-Agamy. Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits.
Human & experimental toxicology.
2017 Nov; 36(11):1131-1145. doi:
10.1177/0960327116681649. [PMID: 27941169] - Christel C L M Boons, Abdel Chahbouni, Anneliene M Schimmel, Abraham J Wilhelm, Yvonne M den Hartog, Jeroen J W M Janssen, N Harry Hendrikse, Jacqueline G Hugtenburg, Eleonora L Swart. Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.
The Journal of pharmacy and pharmacology.
2017 Oct; 69(10):1265-1274. doi:
10.1111/jphp.12757. [PMID: 28643375] - Hayam Ateyya, Zeinab A Hassan, Nagla A El-Sherbeeny. The selective tyrosine kinase-inhibitor nilotinib alleviates experimentally induced cisplatin nephrotoxicity and heptotoxicity.
Environmental toxicology and pharmacology.
2017 Oct; 55(?):60-67. doi:
10.1016/j.etap.2017.08.008. [PMID: 28826126] - S Hu, A F Leblanc, A A Gibson, K W Hong, J Y Kim, L J Janke, L Li, A Vasilyeva, D B Finkelstein, J A Sprowl, D H Sweet, E Schlatter, G Ciarimboli, Jhm Schellens, S D Baker, N Pabla, A Sparreboom. Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.
Clinical and translational science.
2017 Sep; 10(5):412-420. doi:
10.1111/cts.12480. [PMID: 28689374] - Hanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, Perttu Koskenvesa, Tim H Brümmendorf, Bjorn T Gjertsen, Jeroen Janssen, Kourosh Lotfi, Berit Markevärn, Ulla Olsson-Strömberg, Leif Stenke, Jesper Stentoft, Johan Richter, Henrik Hjorth-Hansen, Anna Kreutzman, Satu Mustjoki. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Journal of cancer research and clinical oncology.
2017 Aug; 143(8):1543-1554. doi:
10.1007/s00432-017-2378-6. [PMID: 28337541] - Aneta Wojnicz, Beatriz Colom-Fernández, Juan L Steegmann, Cecilia Muñoz-Calleja, Francisco Abad-Santos, Ana Ruiz-Nuño. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Therapeutic drug monitoring.
2017 06; 39(3):252-262. doi:
10.1097/ftd.0000000000000406. [PMID: 28490048] - Manar A Nader, Heba M Wagih. Nilotinib, a tyrosine kinase inhibitor exhibits protection against acute pancreatitis-induced lung and liver damage in rats.
Naunyn-Schmiedeberg's archives of pharmacology.
2017 Mar; 390(3):291-300. doi:
10.1007/s00210-016-1327-2. [PMID: 27975299] - Sieghart Sopper, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T Gjertsen, Günther Gastl, Matthias Baldauf, Zlatko Trajanoski, Frank Giles, Andreas Hochhaus, Thomas Ernst, Thomas Schenk, Jeroen J W M Janssen, Gert J Ossenkoppele, Kimmo Porkka, Dominik Wolf. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017 Jan; 35(2):175-184. doi:
10.1200/jco.2016.67.0893. [PMID: 28056193] - Mayumi Hatsuse, Yuka Daikoku, Yuta Tamoto, Masahiro Uehara, Takashi Kitani, Keiichi Tamagaki, Shin-Ichi Fuchida, Akira Okano, Satoshi Murakami, Chihiro Shimazaki. Renal artery stenosis following nilotinib administration in a patient with chronic myelogenous leukemia.
[Rinsho ketsueki] The Japanese journal of clinical hematology.
2017; 58(1):15-19. doi:
10.11406/rinketsu.58.15. [PMID: 28190859] - E Y Romero-Ventosa, L Otero-Millán, S González-Costas, P Vilasoa-Boo, A Silva-López, C Arroyo-Conde, G Piñeiro-Corrales. Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients.
Indian journal of cancer.
2017 Jan; 54(1):136-143. doi:
10.4103/ijc.ijc_190_17. [PMID: 29199677] - J Kong, N Chen, H X Fu, T J Hang, M Song, H Jiang. [Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
2016 Nov; 37(11):957-960. doi:
10.3760/cma.j.issn.0253-2727.2016.11.006. [PMID: 27995880] - Ryosuke Nakahara, Yuhki Satho, Hiroki Itoh. High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry.
Journal of clinical laboratory analysis.
2016 Nov; 30(6):1028-1030. doi:
10.1002/jcla.21975. [PMID: 27194024] - Jacqueline E Paramarta, Maureen C Turina, Troy Noordenbos, Tanja F Heijda, Iris C Blijdorp, Nataliya Yeremenko, Dominique Baeten. A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.
Journal of translational medicine.
2016 10; 14(1):308. doi:
10.1186/s12967-016-1050-2. [PMID: 27784336] - Naif Alhawiti, Kate L Burbury, Faith A Kwa, Cindy J O'Malley, Peter Shuttleworth, Mohamad Alzard, Abdullah Hamadi, Andrew P Grigg, Denise E Jackson. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.
Thrombosis research.
2016 Sep; 145(?):54-64. doi:
10.1016/j.thromres.2016.07.019. [PMID: 27494773] - Ivo Vrobel, Hana Janečková, Edgar Faber, Kateřina Bouchalová, Kateřina Mičová, David Friedecký, Tomáš Adam. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
Therapeutic drug monitoring.
2016 08; 38(4):516-24. doi:
10.1097/ftd.0000000000000309. [PMID: 27414975] - Jin Yan, Di Wu, Pingchuan Sun, Xiaoli Ma, Lili Wang, Shanshan Li, Kailin Xu, Hui Li. Binding mechanism of the tyrosine-kinase inhibitor nilotinib to human serum albumin determined by 1H STD NMR, 19F NMR, and molecular modeling.
Journal of pharmaceutical and biomedical analysis.
2016 May; 124(?):1-9. doi:
10.1016/j.jpba.2016.02.024. [PMID: 26922576] - Manar A Nader, Ghalia M Attia. Beneficial effects of nilotinib, tyrosine kinase inhibitor on cyclosporine-A induced renal damage in rats.
International immunopharmacology.
2016 Apr; 33(?):1-7. doi:
10.1016/j.intimp.2016.01.022. [PMID: 26844915] - Koji Sasaki, Amit Lahoti, Elias Jabbour, Preetesh Jain, Sherry Pierce, Gautam Borthakur, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Alessandra Ferrajoli, Susan O'Brien, Hagop Kantarjian, Jorge Cortes. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Clinical lymphoma, myeloma & leukemia.
2016 Mar; 16(3):152-62. doi:
10.1016/j.clml.2015.12.003. [PMID: 26796981] - Irmak Sayin, Meltem Ayli, Ali Kemal Oğuz, Güldane Cengiz Seval. Xanthelasma palpebrarum: a new side effect of nilotinib.
BMJ case reports.
2016 Jan; 2016(?):. doi:
10.1136/bcr-2015-213511. [PMID: 26759444] - A Hochhaus, G Rosti, N C P Cross, J L Steegmann, P le Coutre, G Ossenkoppele, L Petrov, T Masszi, A Hellmann, L Griskevicius, W Wiktor-Jedrzejczak, D Rea, D Coriu, T H Brümmendorf, K Porkka, G Saglio, G Gastl, M C Müller, P Schuld, P Di Matteo, A Pellegrino, L Dezzani, F-X Mahon, M Baccarani, F J Giles. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
Leukemia.
2016 Jan; 30(1):57-64. doi:
10.1038/leu.2015.270. [PMID: 26437782] - Nehal Mohsen Elsherbiny, Mohamed El-Sherbiny, Eman Said. Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib.
Journal of physiology and biochemistry.
2015 Dec; 71(4):635-48. doi:
10.1007/s13105-015-0428-6. [PMID: 26293752] - Gozde Dervis Hakim, Mujde Soyturk, Mehtat Unlu, Pinar Ataca, Meral Karaman, Ozgul Sagol, Elif Borekci, Osman Yilmaz. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model.
World journal of gastroenterology.
2015 Nov; 21(44):12576-85. doi:
10.3748/wjg.v21.i44.12576. [PMID: 26640333] - Musa Yilmaz, Amit Lahoti, Susan O'Brien, Graciela M Nogueras-González, Jan Burger, Alessandra Ferrajoli, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Elias Jabbour, Hagop Kantarjian, Jorge E Cortes. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Cancer.
2015 Nov; 121(21):3894-904. doi:
10.1002/cncr.29587. [PMID: 26217876] - Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, Veronica Resi, Cristina Bucelli, Nicola Orofino, Mariarita Sciumè, Chiara Elena, Valeria Grancini, Dario Consonni, Ester Maria Orlandi, Agostino Cortelezzi. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?.
Oncotarget.
2015 Oct; 6(32):33944-51. doi:
10.18632/oncotarget.5580. [PMID: 26376678] - Hefei Zhang, Jennifer Sheng, Jin H Ko, Cheng Zheng, Wei Zhou, Petra Priess, Wen Lin, Steven Novick. Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.
Journal of clinical pharmacology.
2015 Apr; 55(4):401-8. doi:
10.1002/jcph.434. [PMID: 25418605] - David T Yeung, Michael P Osborn, Deborah L White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K Hiwase, Mark Hertzberg, Anthony P Schwarer, Robin Filshie, Christopher K Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J Forsyth, John Taper, David M Ross, Jennifer Beresford, Constantine Tam, Anthony K Mills, Andrew P Grigg, Timothy P Hughes. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Blood.
2015 Feb; 125(6):915-23. doi:
10.1182/blood-2014-07-590315. [PMID: 25519749] - Yuki Ishii, May Keu Nhiayi, Edison Tse, Jonathan Cheng, Michele Massimino, Donald L Durden, Paolo Vigneri, Jean Y J Wang. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
PloS one.
2015; 10(10):e0140585. doi:
10.1371/journal.pone.0140585. [PMID: 26473951] - Masatomo Miura. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Biological & pharmaceutical bulletin.
2015; 38(5):645-54. doi:
10.1248/bpb.b15-00103. [PMID: 25947908] - Tetsuya Saita, Yuta Yamamoto, Masashi Shin, Yukitaka Nakano. Preparation of Antibodies and Development of an Enzyme-Linked Immunosorbent Assay for the Tyrosine Kinase Inhibitors Lapatinib and Nilotinib.
Biological & pharmaceutical bulletin.
2015; 38(10):1652-7. doi:
10.1248/bpb.b15-00330. [PMID: 26424026] - Gamal E Shiha, Nashwa M Abu-Elsaad, Khaled R Zalata, Tarek M Ibrahim. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight.
Clinical and experimental pharmacology & physiology.
2014 Oct; 41(10):788-97. doi:
10.1111/1440-1681.12286. [PMID: 25115651] - Chen Wenqiang, Irina Lonskaya, Michaeline L Hebron, Zainab Ibrahim, Rafal T Olszewski, Joseph H Neale, Charbel E-H Moussa. Parkin-mediated reduction of nuclear and soluble TDP-43 reverses behavioral decline in symptomatic mice.
Human molecular genetics.
2014 Sep; 23(18):4960-9. doi:
10.1093/hmg/ddu211. [PMID: 24847002] - George M Shopp, Lawrence Helson, Annie Bouchard, Dany Salvail, Muhammad Majeed. Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Anticancer research.
2014 Sep; 34(9):4733-40. doi:
NULL. [PMID: 25202051] - Delphine Rea, Tristan Mirault, Thomas Cluzeau, Jean-François Gautier, François Guilhot, Hervé Dombret, Emmanuel Messas. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.
Haematologica.
2014 Jul; 99(7):1197-203. doi:
10.3324/haematol.2014.104075. [PMID: 24658819] - Sridhar Veeraraghavan, Satheeshmanikandan Thappali, Srikant Viswanadha, Sandhyarani Chennupati, Santhoshkumar Nalla, Manikantakumar Golla, Swaroopkumar Vakkalanka, Manivannan Rangasamy. Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2014 Jun; 94(?):125-31. doi:
10.1016/j.jpba.2014.01.040. [PMID: 24561338] - Chin Kook Rhee, Ji Young Kang, Chan Kwon Park, Sook Young Lee, Soon Suk Kwon, Young Kyoon Kim, Hyoung Kyu Yoon. Effect of nilotinib on airway remodeling in a murine model of chronic asthma.
Experimental lung research.
2014 Jun; 40(5):199-210. doi:
10.3109/01902148.2013.831959. [PMID: 24784417] - Christel C L M Boons, Eleonora L Swart, Lonneke Timmers, Peter M van de Ven, Jeroen J W M Janssen, Jacqueline G Hugtenburg. Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.
BMC cancer.
2014 Apr; 14(?):247. doi:
10.1186/1471-2407-14-247. [PMID: 24712728] - Céline Narjoz, Amélie Favre, Justin McMullen, Philippe Kiehl, Michael Montemurro, William D Figg, Philippe Beaune, Isabelle de Waziers, Bertrand Rochat. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
PloS one.
2014; 9(5):e95532. doi:
10.1371/journal.pone.0095532. [PMID: 24819355] - Maiko Abumiya, Naoto Takahashi, Takenori Niioka, Yoshihiro Kameoka, Naohito Fujishima, Hiroyuki Tagawa, Kenichi Sawada, Masatomo Miura. Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.
Drug metabolism and pharmacokinetics.
2014; 29(6):449-54. doi:
10.2133/dmpk.dmpk-14-rg-031. [PMID: 24898899] - Mark Reinwald, Eberhard Schleyer, Philipp Kiewe, Igor Wolfgang Blau, Thomas Burmeister, Stefan Pursche, Martin Neumann, Michael Notter, Eckhard Thiel, Wolf-Karsten Hofmann, Hans-Jochem Kolb, Stefan Burdach, Hans-Ulrich Bender. Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.
BioMed research international.
2014; 2014(?):637059. doi:
10.1155/2014/637059. [PMID: 25025064] - Jiang Wei, Marcus Freytag, Yvonne Schober, Wolfgang A Nockher, Victor F Mautner, Reinhard E Friedrich, Paul W Manley, Lan Kluwe, Andreas Kurtz. Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.
PloS one.
2014; 9(10):e107760. doi:
10.1371/journal.pone.0107760. [PMID: 25340526] - Yuji Yamakawa, Akinobu Hamada, Takashi Uchida, Daisuke Sato, Misato Yuki, Masahiro Hayashi, Tatsuya Kawaguchi, Hideyuki Saito. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
Biological & pharmaceutical bulletin.
2014; 37(8):1330-5. doi:
10.1248/bpb.b14-00254. [PMID: 25087954] - Hussein A Tawbi, An L Tran, Susan M Christner, Yan Lin, Matthew Johnson, Emily Mowrey, Leonard R Appleman, Ronald Stoller, Brian M Miller, Merrill J Egorin, Jan H Beumer. Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
Cancer chemotherapy and pharmacology.
2013 Nov; 72(5):1143-7. doi:
10.1007/s00280-013-2283-x. [PMID: 24036846] - Pinar Ataca, Mujde Soyturk, Meral Karaman, Mehtat Unlu, Ozgul Sagol, Gozde Dervis Hakim, Osman Yilmaz. Nilotinib-mediated mucosal healing in a rat model of colitis.
World journal of gastroenterology.
2013 Oct; 19(37):6237-44. doi:
10.3748/wjg.v19.i37.6237. [PMID: 24115822]